CTOs on the Move

Avantra Biosciences FKA Decision Biomarkers

www.avantrabio.com

 
Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Center for Functional Genomics

Center for Functional Genomics is a Rensselaer, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verve Therapeutics

Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Headquartered in Cambridge, Mass., with a research facility in Philadelphia.

Blue Sky Biotech Inc

Blue Sky Biotech Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elektrofi

Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company`s founding team of MIT engineers and scientists are shaping the future of biologics delivery.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.